ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS† treatment | boehringer-ingelheim.pt
Skip to main content